SPEAKERS 2nd ANNUAL MedTech & Diagnostics Innovations … · SUPPORTING ORGANISATIONS PRESENTING COMPANIES ORGANISERS WELCOME SPEAKERS 2nd ANNUAL MedTech & Diagnostics Innovations

SUPPORTING ORGANISATIONSPRESENTING COM

PANIESORGANISERS

WELCOM

ESPEAKERS

2nd ANNUAL

MedTech & DiagnosticsInnovations Summit

www.sachsforum.com

13th November 2014Hotel Nikko Düsseldorf

Conference Guide

ME

DT

EC

H &

DIA

GN

OS

TIC

S I

NN

OV

AT

ION

S S

UM

MIT

Welcome


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Request for PresentationsPlease use the agenda to mark off presentations that you are interested in and email your request to [email protected] after the Summit. We will endeavour to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT have copies of the slides that are shown during the Summit.

Sachs Associates are delighted to welcome you to the:

2nd ANNUAL

MedTech & Diagnostics Innovations Summit13th November 2014Hotel Nikko Düsseldorf

General InformationThe registration desk will be open from 8am on November 13th although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.

Networking at the Summit is facilitated by our online 1-2-1 meeting system, which is available to all participants.

Sachs Associates are delighted to welcome you to the 2nd Annual MedTech & Diagnostics Innovations Summit. The Summit provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas.

The program features keynotes from industry leaders and plenary panels on industry acquisitions; public markets, venture investment and growth, company finance, and diagnostics. The subjects of regulation and reimbursement will also be covered.

Apart from the plenary sessions the program features public and private company presentations focused on innovation and alliances/investment opportunities. The MedTech and Device companies track covers; Oncology, Cardiovascular, Imaging, Surgical Devices & Implants. There will be a separate track for diagnostics. These will be held in 2 parallel streams.

There will be many networking opportunities. There is a 1-to-1 online meeting system with meeting rooms provided. In addition, there will be networking breaks and a conference reception.


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Events Diary

3rd Annual Cancer Bio Partnering and Investment ForumPromoting Public & Private Sector, Collaboration & Investment in Drug Development23rd February 2015 • New York Academy of Sciences • USA

The 2nd Annual Sachs Cancer Bio Partnering Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment. We expect around 300 delegates and there is an online meeting system and meeting facilities to make the event transactional. There will also be a track of presentations by research institutes, patient advocacy groups, pharmaceutical companies on partnering and biotech’s seeking licensing/investment.The Forum will feature an online one-to-one meeting system with designated meeting space available to all attendees.

The Forum will cover the following topics in the program: • Advances in Translational Research • Strategies for Small Molecule and Biologicals Drug Development • Deal Making • Public & Private Partnerships • Diagnostics • Immunotherapies and Cancer Vaccines • Case Study

8th Annual European Life Science CEO Forum & ExhibitionPartnering & Investing in Biotech & Pharma Industry3rd – 4th March 2015 • Hilton Zurich Airport Hotel • Switzerland

Back for its eighth year, this exclusive and highly transactional partnering event is a must for companies wishing to meet with their peers, engage with leading investors and forge new partnerships.

Building on the success of this year’s event, the forum will provide an excellent platform to gain insight into partnering and investment trends in the Biotech and Pharma industry. Networking at the Forum is facilitated by our online 1-2-1 meeting system, which is available to all participants.

The conference will feature up to 80 presentations by large to mid size pharmaceutical companies looking for strategic alliances/partners.

Do not miss out on this great opportunity to meet emerging companies, leading global investors and Big Pharma representatives!

For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Mina Orda on [email protected]


PANIESORGANISERS

WELCOM

ESPEAKERS

Speakers

t back :: next u

Albert Lauritano, Director at BD Technologies, Becton Dickinson

Albert Lauritano is responsible for identifying, negotiating and establishing global, external relationships that support BD’s strategic innovation, technology and capability needs. He also directs BD’s technology accelerator and incubator programs as alternative business model partnerships for the entrepreneurial, investor, university and startup communities. Earlier this year, he established the unique technology partnerships for BD within the State of Israel, establishing the BD-Microsoft Healthcare Accelerator and becoming a corporate partner with the Office of the Chief Scientist to fund new technology R&D.

Al joined BD in 2003 and has over 35 years of experience in the pharmaceutical, biotechnology and medical technology industries. Prior to joining BD, he held executive business development positions at Amylin Pharmaceuticals, Icagen and D-Pharm Ltd after starting his career at Novo Nordisk Pharmaceuticals where he served in senior clinical, marketing and business development positions in the US, Canada, Europe and Japan.

Al has a BS in Biology from Fairleigh Dickinson University and an MS in Pharmacology from Rutgers University; he has published widely in the field of diabetes. He received his Certified Licensing Professional credential in 2007 from the Licensing Executive Society and is also a member of the Association of University Technology Managers.

Amir Nashat, Managing Partner, Polaris Partners

Amir is a Managing Partner in the Boston office. Amir joined Polaris in 2002 and focuses on investments in healthcare.

Amir serves on the Partners Innovation Fund and is a Catalyst of the Deshpande Center for Technological Innovation at MIT. He previously served on the Board of the New England Venture Capital Association. He has been named to the Forbes Midas list of Top 100 Venture Capitalists and is also on the Innovation Advisory Board of Partners Healthcare.

Amir is a board member of the following Polaris portfolio companies: AgBiome, aTyr Pharma, BIND Therapeutics, (NASDAQ: BIND), Fate Therapeutics (NASDAQ: FATE), Promedior Pharmaceuticals, Scholar Rock, Selecta Biosciences and Sun Catalytix. Additionally, Amir has served as a Director of Adnexus Therapeutics (acquired by Bristol Myers Squibb), Athenix (acquired by Bayer), Avila Therapeutics (acquired by Celgene), Living Proof, Pervasis Therapeutics (acquired by Shire Pharmaceuticals) and served as a Board Observer of GI Dynamics (GID.AX). In addition to his role as an investor, Amir has also served as the initial CEO of Living Proof (known as Andora at the time) and Sun Catalytix .

Amir completed his Ph.D. as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Amir also earned both his M.S. and B.S. in Materials Science and Mechanical Engineering at the University of California, Berkeley.

Anat Naschitz, Managing Director, Orbimed Healthcare Fund Management

Anat Naschitz is a Managing Director at OrbiMed. OrbiMed is the world’s largest healthcare investment firm with over $11 billion under management across public and private asset classes. The firm covers the entire healthcare spectrum, investing in biopharmaceuticals, medical devices and health IT. Anat has over 19 years of healthcare experience, with a particular passion for digital health. She currently serves on the boards of Treato – patient big data analytics, Tyto – mobile telemedicine device – and Medigus – surgical endoscopy.

Prior experience includes seven years with McKinsey & Company in London, where she was an Associate Partner, managing strategy and M&A projects for senior management of the world’s preeminent pharmaceutical and biotechnology companies. Among other accomplishments, Anat led pharmaceutical spinout work resulting in the creation of two European biotech companies, which subsequently had IPOs for over $1 billion. Post McKinsey Anat joined Apax Partners, where she focused on life sciences investments. Subsequently Anat served as a director/advisor to the boards of life science companies and investors. She earned her M.B.A. at INSEAD and her LL.B. at Tel Aviv University.


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Speakers

Antoine Papiernik, Managing Partner, Sofinnova Partners SA

Antoine Papiernik is a Managing Partner at Sofinnova Partners, which he joined in 1997. Antoine has been an initial investor and active board member in public companies like Actelion, Auris, ProQR, NovusPharma (then sold to CTI), Movetis (then sold to Shire), Mainstay, Pixium Vision and Stentys, which went public respectively on the Zürich stock exchange, the NASDAQ, the Milan Nuovo Mercato, the Belgium Stock Exchange, the Dublin Stock Exchange and EuroNext Paris, in Cotherix (initially NASDAQ listed, then sold to Actelion), CoreValve (sold to Medtronic), Fovea (sold to Sanofi Aventis) and Ethical Oncology Science (EOS, sold to Clovis Oncology). He has also invested in and is a board member of private companies ReCor, MD Start, Shockwave Medical, and Reflexion Medical and ProQR. Antoine has an MBA from the Wharton School of Business, University of Pennsylvania. In 2012 and 2011, Antoine was selected by Forbes for its “Midas List” of the world’s top venture capital investors. Antoine is one of the only Europeans on the list, and one of the few life science investors as well.

Beat Merz, Managing Director, Rockport Venture Partners

Dr. Merz joined Rockport in 2013 as Managing Director of Rockport Venture Securities and Head of European Equity. Dr. Merz brings 15 years of experience in venture and growth stage equity financing and operations to Rockport, including management and leadership of over $150 million in equity financings. Prior to joining Rockport, Dr. Merz was a Partner with Ares Life Sciences. Previously, he was responsible for venture and private equity investment management as Investment Advisor of HBM Partners. Prior to joining HBM Partners, he was Managing Director of NMT New Medical Technologies, where he provided capital, professional management consulting and start-up support for young medical device companies. During his career he has directed investments in the US, Europe and Israel-domiciled companies and has served as co-founder or has held board seats for many of them. He currently serves or has served on the Boards of Directors of Micrus Endovascular (acquired by JNJ), Thommen Medical (acquired by private investors), Asthmatx (acquired by BSX), Precimed (acquired by Greatbach), Devax (acquired by BioSensors), BioControl Medical, South Eastern Technologies and several other medical device companies. Dr. Merz holds a Ph.D. in biomechanics from ETH Zurich/Switzerland and an MBA from the University of Strathclyde, Glasgow/UK.

Benjamin Sarda, Director of Marketing for Orange Healthcare, France Telecom SA

Benjamin Sarda is Director of Product Marketing at Orange Healthcare where he is responsible for defining and leading the eHealth product development roadmap along with identifying market entry strategies across the healthcare ecosystem

Orange Healthcare aims to develop e-health activities in France and internationally by leveraging the Orange group’s expertise in Information and Communication Technologies.

Prior to Orange Healthcare, Benjamin led the creation of Orange Assistance, an Orange subsidiary providing home computer assistance services to Orange customers. Benjamin has held various director-level positions within Orange.

Before joining the Orange group, Benjamin worked in the area of medical imaging at INSERM (Institut national de la santé et de la recherche médicale), a publicly funded medical research entity in France.

Benjamin is frequently invited to speak on the transformational impact of new technologies on the healthcare ecosystem.

He began his career as a system engineer at Eutelsat, a satellite telecommunications operator.

Benjamin is a graduate of the Ecole Nationale Supérieure des Telecommunications de Bretagne and holds a MS in signal processing.


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Speakers

Daniel O’Mahony, Partner, Seroba Kernel

Daniel O’Mahony is a Partner at Seroba Kernel Life Sciences Limited and brings a wealth of experience in product development, strategic planning, licensing, corporate venturing, intellectual property management and commercialization.

Daniel has been involved in corporate venture at Elan Corporation from 1996-2003; he was an advisor and consultant to Kernel Capital venture capital fund since 2001, focusing on investments in life sciences. He joined Kernel Capital as Partner in 2008 and Seroba Kernel Life Sciences as Partner in 2009. Daniel currently sits on the board of Apica Cardiovascular Ltd, Covagen AG, Novate Medical Ltd, PQ ByPass Inc and is a former board member of a number of companies.

Recent exits include Apica which was acquired by Thoratec in July 2014, Covagen AG which was acquired by Cilag/Johnson & Johnson in August 2014 (amount undisclosed) and Stokes Bio which was acquired by Life Technologies.

Daniel graduated with a Ph.D. from the National University of Ireland, Cork in 1986 and holds a business degree in technology management from the Smurfit Business School, University College Dublin (2000). He has held academic appointments at the Genetics Department, Trinity College, Dublin, the Weis Research Centre, Geisinger Clinic, Pennsylvania, USA and the Department of Medicine & Experimental Therapeutics at University College. He has published in several scientific journals and is co-inventor on numerous patent families.

Brian Russell, Vice President Business Development Wireless Respiratory and Monitoring Solutions, Covidien

Brian is currently the Vice President of Wireless Healthcare in the Patient Monitoring division of Covidien.

Over the past two decades Brian Russell has commercialized ground breaking technology products for Covidien (USA), Zephyr Technology Corporation (USA) , Nokia Telecommunications (Cambridge, England) and Analog Devices Inc (USA)

Zephyr was acquired by Covidien in March 2014 for its global leadership in the area of wearable remote physiological monitoring solutions. Mr. Russell was the CEO and founder of Zephyr Technology since 2003 to its acquisition. The groups solutions draws from Zephyr’s decade of experience remotely monitoring Special Forces, First Responders, Professional Sports and patients, where ever there is a need to measure life anywhere.

Mr. Russell received his Bachelor of Engineering at Auckland University, New Zealand; and is a subject matter expert in analog electronics, communications and physiology. He holds multiple patents in the area optics, physiological sensing and wearable sensors.

David Peoples, VP, Healthcare Investment Banking, JP Morgan

David is a Vice President in J.P. Morgan’s Healthcare Investment Banking Team based in London and is focused on the Medical Devices and Diagnostics sectors.

He has 11 years of healthcare investment banking experience and has advised clients on a broad range of M&A and capital markets transactions.


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Speakers

Gilad Peleg Lorberbaum, Chief Operating Officer, Rainbow Medical

A seasoned Life Sciences executive, with a broad and diverse experience base over 20 years, from blue chip corporate business development, to start up innovation and venture capital management

Currently as C.O.O. at Rainbow Medical (www.rainbowmd.com), Gilad is part of the management team at an operational investment company that has innovated, incorporated and invested in 12 portfolio companies, developed over 25 pipeline projects, with total investments toping $ 100M;

At RMD Gilad manages the screening and investment committee process, the group intellectual property portfolio, as well as ongoing management of the portfolio companies, from design to clinical studies, accelerating value creation.

Prior to RMD, Gilad was CEO in residence, with at the Glenrock Family Office Life Sciences team, involved with biotechnology, Ag-Bio, and medical device companies.

In 2002, Gilad was CEO of NanoCyte Inc., an unrivaled topical drug delivery platform technology start up, leveraging micron size sea life injectors for effective trans-dermal delivery of pharmaceuticals and cosmetics, where Gilad led the company from idea to clinical proof of concept and strategic licensing;

Prior to, Gilad was Vice President at Reico Ventures, managing a portfolio of med-tech companies, adding value to the portfolio, and leading strategic transactions.

Thereafter, Gilad was part of a Founder team managing a cancer detection technology turnaround, which was acquired by a strategic corporate.

In 1993 Gilad joined Teva Pharmaceutical (NASDAQ: TEVA), as finance manager of the R&D division, managing a budget of $ 50 M, and initiating global joint development agreements. Further on at Teva Pharmaceuticals, Gilad was the first member of the corporate business development team formed back in 1995, assessing and executing several of Teva’s most substantial M&A transactions over a period of 5 years.

Gilad earned a Bachelor’s degree in Economics from the Hebrew University of Jerusalem, Israel, and a Masters degree in Business Administration, from the University of Hartford, Connecticut USA.

Gilad is married, with 2 daughters, and resides in Israel.

Frank Bulens, Partner, Health-tech Investment Practice, Capricorn Venture Partners NV

Frank Bulens joined Capricorn Venture Partners in 2009 and is a member of its management committee and board of directors. Frank is actively involved with health technology companies in the broad sense ranging from diagnostics, therapeutics and medical devices for the Capricorn Health-tech Fund and the Quest for Growth Fund as well as digital health-tech for the Capricorn ICT Fund.

Previously, he was a member of the life science venture capital team at Gimv (Antwerp, Belgium) for a period of 11 years and most recently as an executive investment manager. Before joining Gimv he worked one year at the IWT, a research fund organization in Brussels, as a senior scientific advisor. Prior to IWT Frank worked 10 years at the Faculty of Medicine, University of Leuven as a PhD and postdoctoral researcher. Before that Frank worked two years in the food industry. Frank is trained as an industrial engineer in chemistry/biochemistry and obtained a Master Degree as well as a PhD in Medical Sciences at the University of Leuven, Belgium.

Throughout his 15+ years of making active venture capital investments Frank collected a vast experience in building early stage tech companies towards a successful exit through a trade sale or an IPO. His past board memberships involved a number of companies such as Ablynx in Belgium, Arrow Therapeutics in the UK, Innate Pharma and Fovea Pharmaceuticals in France as well as Aclara Biosciences and X-Ceptor in the US.

Current board memberships include Sequana Medical (Switzerland), Trinean (Belgium), TROD Medical (Belgium) and Prosonix (UK, observer).


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Speakers

Klaus Stoeckemann, Managing Partner, Peppermint Venture Partners GmbH

Klaus Stoeckemann is a co-founder and Managing Partner of Peppermint VenturePartners (PVP) (www.peppermint-vp.com). PVP focuses on investments in medical device and digital-health start-up companies in Germany and Europe. As a former General Partner in the 3i Healthcare Venture Capital team, he is a highly experienced venture capitalist with more than 13 years of experience in the Venture Capital industry. He was responsible for more than 12 investments and exits during his tenure at 3i. His track record at 3i includes the IPO of companies like Epigenomics and Jerini as well as the trade sales of Evotec Neuroscience, Amaxa and Elbion. Klaus has been board member of Combinature, Epigenomics, Jerini, Amaxa, Immatics as well as IntelliDx and Zonare in the US. He is currently chairman of the boards of Humedics, Emperra E-Health Technologies as well as Caterna Vision and board member of Implandata and focuses on digital health and medical device investments across Europe. In addition he is mentor at the first vertical medical accelerator eyefocus based in Berlin (www.eyefocus.co). Klaus holds a PhD in Biology and Pharmacology from the University of Mainz as well as a MBA from WHU / Kellogg Northwestern University in the US.

Janke Dittmer, Partner, Gilde Healthcare Partners

Janke Dittmer is a Partner with Gilde Healthcare and is focused on investing in MedTech, Diagnostics, Digital Health and Home Healthcare businesses. Prior to joining Gilde, he was a Venture General Manager and Head of Business Development & Strategy within Philips’ Healthcare Corporate Venturing unit. On top of shaping the strategy, he was responsible for selecting new investment opportunities. He also started and lead two ventures in the fields of cardiology and sepsis. Before his time at Philips, Janke was an Engagement Manager at McKinsey & Company advising leading High Tech players on growth strategies and strategic marketing. Janke cofounded a Nanotech company in the Silicon Valley after serving as a Fellow at the Lawrence Berkeley National Lab. He earned a PhD in Physics from the University of Cambridge in the UK and did a Post-Doc in Nanotechnology at the University of California, Berkeley. Janke is one of the founders and a council member of the International Venture Club and has advised the European Commission on innovation policy.

Josep Sanfeliu, General Partner, Ysios Capital Partners

Josep L.l. Sanfeliu focuses on medtech investments and on structuring transactions.

Josep serves on the board of MedLumics and CVRx. Formerly, he was member of the board of Sabir Medical and board observer at Endosense (now St.Jude Medical).

Josep has close to 20 years of experience in law, corporate finance and business development in connection with entrepreneurs and with intellectual property related companies. Before joining Ysios, Josep worked for the pharma and healthcare industries, in areas such as business and corporate development and operations. This included managerial positions at Almirall and SAR-Quavitae. Joe also worked at Cuatrecasas, KPMG and Eurohold Corporate Finance, where he was involved in mergers and acquisitions, and financing of innovation and technology.

Josep holds a degree in Law from Universitat Pompeu Fabra of Barcelona, a Master of Laws (LL.M) degree from the University of Michigan at Ann Arbor, and an MBA (GEMBA) from IESE (University of Navarra).

Jørgen Thorball, CEO, Ophiuchus Technologies AG

Dr. Jørgen Thorball (52), CEO Ophiuchus Technologies AG and Managing Partner in XOventure AG has served 30 years in life science from international corporate management positions in the pharmaceutical industry (Pharmacia and Aventis) managing billion dollar products to build +30 companies as serial entrepreneur.

In 2010 Thorball was awarded the Medicon Valley Cross Border Award for his achievements in Denmark and Sweden.

XOventure build life science companies among those are the worlds most advanced cell therapy company Ophiuchus Technologies AG to a company with a very simple and ingenious concept from 1CryoBio.


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Speakers

Markus Hosang, General Partner, BioMedPartners

Dr. Markus Hosang is a General Partner at BioMedPartners AG in Basel, Switzerland. He has strong experience and broad knowledge in strategic and operational aspects of the venture capital business, as well as in pharmaceutical research and in many product development and marketing areas, with special expertise in the areas of biotechnologies, strategic alliances, and theranostics/diagnostics. Before joining BioMedPartners in 2004, Dr. Hosang was a Venture Partner at MPM Capital, where he managed the firms European office in Munich, was co-responsible for their European deal flow, and served on the boards of several European portfolio companies. Previously, he was at Roche in Basel, where, for nearly 20 years, he held several senior management positions of increasing importance in the Pharma R&D organization, including Vice President and Director of Global Pharma Research Strategic Unit and Chief of Staff to the President of Pharma R&D, member of the Global Board of R&D Directors, Head of Development Projects in Basel and Member of the Roche Pharma Portfolio Board, and most recently, as a Deputy Head and Chief Scientific Officer of Pharma Genetics and Integrated Medicine, and a member of the Roche Genetics Executive Committee.

He obtained his Ph.D. in Biochemistry from the ETH in Zurich with summa cum laude and pursued his postgraduate training at Stanford University Medical School in neurobiology and subsequently at the University of Washington in Seattle in vascular diseases. Dr. Hosang served on the Board of Directors and the Board of Trustees of the Swiss Foundation for Stipends in Medicine and Biology (SSMBS) as its Treasurer from 1994-2002. He currently is a member of the boards of Aleva Neurotherapeutics AG, Anergis SA, Biotectra AG, Imevax GmbH and Suppremol GmbH. Earlier he was on the boards of Okairos (until its acquisition by GSK in May 2013), Omrix, Kourion (until its merger with ViaCell), IDEA, Atugen, Avontec and Neuraxo. He has published more than 30 articles in peer reviewed journals, and is coinventor on several patents.

Martien van Osch, Managing Partner, Forbion Capital Partners

Martien spearheads the medical device related activities at Forbion and acts as the CFO. He was responsible for the recent exit Santaris Pharma AS to Roche in August 2014 for up to USD 450 million, the sale of Circulite inc to Heartware inc in December 2013 for up to USD 350 million and of Pathway Medical Technologies, Inc., sold to Bayer Medrad in 2011 for USD 125 million. He currently actively contributes to the boards of Mitralign Inc. and PneumRx, Inc.His experience in the life sciences industry also includes prior non-executive board positions at Cambridge Drug Discovery Ltd (sold to Biofocus Plc in 2001), Impella Cardiosystems (sold to Abiomed, Inc. in 2005), Acadia Pharmaceuticals (IPO on Nasdaq in 2004) and Flowmedica, Inc. (sold to Angiodynamics in 2009). Martien holds a degree in Econometrics from the Rijksuniversiteit Groningen, the Netherlands

Laurent Choppe, Managing Partner, Cukierman & Co. Life Sciences

Laurent is leading Cukierman & Co. Life Sciences since 2008 and was involved in all Israeli and international medical device and biotech transactions for the Cukierman group. He brings an extensive international life science experience in managing multifunctional teams and setting up new businesses in pharmaceuticals, biotechnology, nutraceuticals, animal health and direct-to-consumer markets. After a veterinary practice and a new venture management experience, he joined Schering-Plough in 1994 by leading the marketing of major drugs in dermatology, allergy, respiratory and animal health in France, became General Manager in Israel and moved up to Vice President, Virology, Oncology and Cardiology in Canada. He then served as the General Manager of the international headquarters of BELLUS Health (ex-Neurochem NASDAQ & TSE), a global pharmaceutical and nutraceutical company addressing unmet needs in Alzheimer’s disease, AA amyloidosis, diabetes, memory and cognition.

Dr. Choppe is a Doctor of Veterinary Medicine of the University Paris XII, laureate of the École Nationale Vétérinaire d’Alfort, CES of Veterinary Ophthalmology and earned a MBA from INSEAD in Fontainebleau (France). He is married, father of 3 and lives in Lausanne (Switzerland).


PANIESORGANISERS

WELCOM

ESPEAKERS

Speakers

t back :: next u

Matthew Kim, Founder and Executive Chairman, Board of Directors, Vigilant Biosciences

Inspired by both his parents’ battle to overcome their affliction with oral cancer, Matthew H.J. Kim founded Vigilant Biosciences, Inc. and currently serves as the company’s Chairman and CEO. Mr. Kim, a seasoned business and legal executive as well as serial entrepreneur, brings experience encompassing IP management, technology transfer, due diligence, business and corporate development. Prior to Vigilant Biosciences, Mr. Kim founded AerovectRx Corporation, the first spin-off company from the Centers for Disease Control and Prevention (CDC) licensing a unique and ground breaking medical device platform technology, raising a venture staged seed round financing (leveraging an additional $5MM+ in non-dilutive financing), enhancing the company’s IP strategic positioning, and procuring the company’s initial business development deals. Prior to AerovectRx, Mr. Kim founded IP Guidance, a strategic intellectual property asset management consulting group focusing primarily on the management and leverage of IP assets for value creation. Mr. Kim received his Bachelors in Biology at Washington University in St. Louis (Missouri, USA) and his Juris Doctorate at Georgia State University (U.S.A.) and is licensed to practice in Georgia and before the U.S. Patent and Trademark Office.

Miriam Goerlich, Director Business Development / M&A, GE Europe

Miriam Goerlich joined GE Europe in 2011 as Director Business Development / M&A. She is working together with sector teams on growth opportunities in Europe through partnerships, joint ventures and acquisitions across the business spectrum of GE. Since she joined GE she was involved in several acquisitions as well as divestitures across Europe.

Miriam Goerlich started in Investment Banking 2000 at HSBC, moved to Commerzbank and also worked for Société Générale in Frankfurt, Paris and London. Miriam has more than ten years of M&A / Equity Capital Market experience. Her main advisory roles in M&A have been in the health care and renewable energies/ utilities sectors.

She has a Master degree in Finance and International Accounting from Westfälische Wilhelms-University in Münster, Germany. She was scholar of the German National Academic Foundation and McKinsey College.

Neil Butler, CEO, Spectromics

Serial medical diagnostic company executive leading the management of venture backed point-of-care companies from start-up for the past 15 years. He formed Spectromics in April 2014 and joined the board as CEO and initial investor, after working with the founding scientists for almost 3 years on the technology. Attracted by the technology’s differentiation and game changing rapid 10 minute test for detection of bacterial infections and related antibiotic susceptibility. Prior to this he was founding CEO of Vivacta which was acquired by Novartis in 2012. Before Vivacta he was founding CEO of Oxford Biosensors.

He currently also holds a number of board positions with diagnostic companies including: Chairman of Atlas Genetics, Supervisory Board member and audit committee chairman of Genomic Vision (Euronext listed public company), Director of Radisens Diagnostics. He also advises multiple venture capital companies on diagnostics and related technologies.

Martin Pfister, Senior Investment Manager, High-Tech Gruenderfonds

Dr. Martin Pfister joined the High-Tech Gruenderfonds (HTGF) in Bonn in 2010. HTGF is the largest European Seedfonds with about 580 Mio EUR under management and more than 230 active portfolio companies with significant growth potential. As part of the LifeSciences team, Martin Pfister is responsible for the investment and support of currently 12 companies in Biotech, Medtech and e-health.

Dr. Pfister has more than 15 years experience in the life sciences industry. Before joining the HTGF, he has worked in the biotechnology/diagnostics industry, where he held several management positions in start-up companies. He has co-founded two companies in the Dx and healthcare services field and was head of biosaxony to foster the Life Sciences/Pharma industry in Saxony, Germany. Dr. Pfister studied a combination of Medicine, Pharmacy an Biology in Germany and New York University, Medical School and gained his PhD in Immunology from the University of Leipzig.


PANIESORGANISERS

WELCOM

ESPEAKERS

Speakers

t back :: next u

Pekka Rönkä, Chairman of the Board, Magnasense Technologies OY

Pekka Rönkä (born 1952) started his professional career in diagnostics already before graduating from Helsinki University of Technology (M.Sc.E.E.). Pekka has led several global businesses in diagnostics covering clinical chemistry, infectious diseases, specialty testing and laboratory automation. Pekka has also led businesses providing tools for diagnostics research for example microplate instrumentation, PCR, qPCR and magnetic separation. During 13 years at Thermo Fisher Scientific Pekka led four global businesses before retiring and focusing on board memberships within medical technology companies.

Phil Huber, Director of Finance & Operations, Sequana Medical AG

Phil Huber is a seasoned medical device executive with a strong financial background and a passion for overall company operations. Phil has over ten years of experience as CFO and COO in medical device start-ups in Switzerland and Germany. He is responsible for Sequana Medical’s finances, legal affairs, IT, manufacturing and engineering. Prior to joining Sequana Medical, he was appointed as CFO and COO for Ilias Medical GmbH and Cardiola AG. Phil holds an M.A. in Business Administration from the University of Zurich.

Thomas Taapken, CEO & CFO, Epigenomics

Dr. Thomas Taapken is CEO of Epigenomics AG since September 2012. He joined Epigenomics on April 1, 2011 as Chief Financial Officer from Biotie Therapies (Finland), where he held the position of CFO and was a member of the Executive Management Team. He was appointed to this position in 2008, following a business combination between Biotie Therapies and elbion NV, where Thomas had been CFO since 2005. His extensive international experience in the life sciences industry includes previous positions as investment partner at DVC Deutsche Venture Capital from 2003 to 2005 and San Francisco-based US venture capital firm Burrill & Company from 1998-2002. He also worked several years at Sanofi-Aventis in the U.S.A. and Germany, managing corporate venture capital activities, as well as in the areas of corporate & business development and research. Throughout his career, he has been involved in numerous transactions spanning acquisitions, mergers, divestitures, as well as private and public offerings.

Tim Haines, Partner, Abingworth LLP

Tim Haines has more than 25 years of international management experience in the life sciences industry. Before joining Abingworth in 2005 he was Chief Executive of the Abingworth portfolio company, Astex Therapeutics. Tim was with Astex for more than five years and was instrumental in establishing it as one of the leading UK biotechnology companies. Previously, Tim was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe, including CEO of Thackray Inc and General Manager Baxter UK. Current and past board positions include Astex Pharmaceuticals, Fovea, Kspine, Lombard Medical, Pixium Vision, PowderMed, Sientra, Stanmore Implants and XCounter. Tim has a BSc from Exeter University and an MBA from INSEAD. At Abingworth, he identifies and creates new businesses and provides support for portfolio companies.

Otto Skolling, Vice President Business Development, Karolinska Development AB

Otto is Vice President Business Development. He has some 20 years of broad-based Pharmaceutical & Med. Tech. industry experience, including product development, business development & project management gained through management positions at Novozymes, Siemens Life Support Systems and Pharmacia & Upjohn. Mr. Skolling received his MSc. in Chemistry from the Royal Institute of Technology, Stockholm, Sweden.


PANIESORGANISERS

WELCOM

ESPEAKERS

Speakers

t back :: next u

Walter Tabachnik, Board Member, Medasense Biometrics Ltd.

Walter Tabachnik CFA, Medasense VP Business Development & CFO, Board Member Mr. Tabachnik is the former Executive Vice President and Chief Financial Officer of Oridion Systems, a successful patient monitoring company. Mr. Tabachnik led their successful acquisition by the global healthcare company, Covidien, for $346 Million in 2012. He later served as Covidien’s Director of Strategy and Portfolio EMEA. Mr. Tabachnik has previously held a number of senior accounting positions in various distinguished firms in Israel and South Africa. Education: Certified Public Accountant in Israel, B.Sc. Accounting and Economics Hebrew University of Jerusalem, Israel.


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Acarix A/Swww.acarix.com

CONTACTStig Visti Andersen CEO

ADDRESS Diplomvej 376 Kongens Lyngby 2800 Denmark

EMAIL [email protected]

YEAR FOUNDED2009

FINANCIAL SUMMARY

Spinout from Coloplast A/S,

After spinout the company has so far raised 10.5 mill € from VCs and grants.

First commercial sale expected end of 2015.

COMPANY PROFILE

ACARIX A/S is a Copenhagen Denmark based medical technology company dedicated to create acoustics based diagnostic tests that can identify vascular diseases early, fast, effectively and at affordable cost.

One in five persons die from Coronary Artery Disease (CAD): one in four of these dies without any warning from so-called ‘sudden death’.

ACARIX’s innovation is designed to allow for early detection of CAD by recording and categorizing turbulent noise, so called “murmurs” associated with narrowing or clogged arteries

Acarix´s CADScor System aims to become the first line of diagnostic assessment for CAD

ACARIX holds seven acoustic monitoring patent families, including acoustic monitoring of heart signals, segmentation of cardiac acoustic signal, system design, and adhesive patches for monitoring acoustic signals. ACARIX owns the core patents on its CADScor® System for all medical applications. This constitutes a robust platform technology with a multitude of potential follow-on applications.

The CADScor® System comprises an acoustic sensor and a specially designed patch designed to identify the weak turbulent noises from blood flow in partially blocked coronary arteries.

The noise pattern is mathematically converted to a cardiac murmur score, indicating the patient risk of suffering from CAD. The total testing time is less than 10 minutes. Combining superior recordings by use of a sensor system and automated acoustic analysis is entirely new to the field of heart diagnosis.

The technology has been validated in initial clinical trials for non-invasively identifying major stenosis verified by coronary angiography. Currently the company is running further studies for marketing support that will include over 2000 patients during 2014-15.

TYPE OF COMPANY

Private

DEVELOPMENT FOCUS

Diagnostic tools for non-invasive assessment of presence of coronary artery disease.

INVESTMENT & LICENSING OPPORTUNITIES

ACARIX is open to developing strategic partnerships that continue to strengthen its clinical development plan spanning symptomatic and high risk asymptomatic patients and leading to commercialization starting in late 2015.

PRODUCT PIPELINE

The CADScor® System comprises an acoustic sensor and a specially designed patch designed to identify the weak turbulent noises from blood flow in partially blocked coronary arteries.

The product is expected to be CE marked late 2014/early 2015.

MANAGEMENT

Stig Visti Andersen, CEO Claus BV Christensen, COO


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Autonomic Technologies, Inc.www.ati-spg.com

CONTACTBenjamin Pless CEO

ADDRESS 3698 Haven Ave Redwood City 94063 USA

TELEPHONE +650 396 4290


YEAR FOUNDED2008

FINANCIAL SUMMARY

Venture Capital funded.

COMPANY PROFILE

Autonomic Technologies is a venture capital funded private company based in Redwood City, California. Our first product is a minimally invasive, insertable microstimulator for the treatment of severe headache.

TYPE OF COMPANY

Private

DEVELOPMENT FOCUS

ATI makes products that exploit the autonomic nervous system to treat disease.


Currently raising a D Round of financing. Equity investment and strategic opportunities available.

PRODUCT PIPELINE

Pulsante™ microstimulator system for the treatment of severe headache is being commercialized in Europe and is undergoing clinical trials in the US.

MANAGEMENT

Ben Pless, CEO Karl Schweitzer, CCO Craig Patterson, CFO


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Medasense Biometrics Ltd.www.medasense.com

CONTACTWalter Tabachnik VP Business Development

ADDRESS 1 Ha’dekel St. Ramat Yishai 3009500 Israel

TELEPHONE +972-4-903-8800

FAX +972 4 903 8808


YEAR FOUNDED 2008

FINANCIAL SUMMARY

To date, Medasense has raised US$ 4.5M. Medasense is planning a new round of financing of $8M in 1H/2015.

COMPANY PROFILE

Medasense has developed a patented, non-invasive platform technology enabling objective assessment of pain in sedated and in conscious patients. Until now, clinicians have had to rely on a patients’ subjective assessment or their own judgment where patients are unable to communicate (under sedation, mentally ill, etc.). Better assessment of pain can contribute to improved clinical outcomes and a reduction in costs associated with non-optimal pain management. As pain is considered the 5th Vital Sign, there is a general consensus that pain monitoring will become a standard of care, similar to other common monitoring devices that monitor the vital signs of blood pressure and heart rate.

Medasense’s technology collects information through a finger-mounted probe that monitors changes in physiological parameters affected by pain and by analgesic medications. Proprietary artificial intelligence algorithms convert the physiological data to a real-time Pain Index. This enables clinicians to improve patient management by properly and timely adjusting pain medications and minimizing adverse events. The technology is implemented in standalone devices or will be embedded in third-party patient monitoring systems.

During the last six years of research, the company has demonstrated the feasibility of its technology to objectively assess changes in acute and chronic pain in both sedated and conscious patients. Data suggests that the Medasense Pain Index is considerably more accurate than any other commercial technology available. Most recently the company completed two validation studies (total 157 patients) in patients undergoing surgical procedures. Data demonstrates significant correlation (p<0.001) of the Pain Index with changes in nociception pain caused by surgical stimulation and the level of analgesics. Further on-going validation studies are being performed in major medical centers in the U.S., Europe and Israel.

The markets for pain monitoring devices include hospitals, pain clinics, medical specialists’ office and homecare. Medasense’s initial market is the hospitals, with a total available U.S. market for bedside pain monitors and related sensors estimated to exceed $1.2 billion and an estimated worldwide market of $4 billion.

Within the hospital market, Medasense is first targeting critical care – starting with operating rooms and proceeding to PACU and ICU’s. These markets represent the optimal entry point for pain monitoring, considering the acuity of the patients, the needs of anaesthesiologists and critical care specialists, and the reliance of hospital’s based physicians and nurses on monitoring technologies to help manage patients’ care. Clinical experience and studies have demonstrated that objective and timely information of changes in pain level contribute to fewer adverse events, reduced costs, faster recovery and an overall greater patient’s satisfaction.

The Medasense monitor will likely be classified by the FDA as a Class II device, requiring 510(k) Premarket Notification. A Pre-Submission meeting with the FDA is expected in Q1/2015 and CE approval is expected by H2/2015. The company also plans to conduct a pivotal study of its technology during 2015 and start commercialization in 2016.

TYPE OF COMPANY

Private

DEVELOPMENT FOCUS

Medical device, Pain monitoring solutions, Pain management care.


Seeking shareholder investment and co-operation with pharmaceutical and medical device companies in the field of pain management.

Continued...


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Medasense Biometrics Ltd.www.medasense.com

CONTACTWalter Tabachnik VP Business Development

ADDRESS 1 Ha’dekel St. Ramat Yishai 3009500 Israel

TELEPHONE +972-4-903-8800

FAX +972 4 903 8808


YEAR FOUNDED 2008

...continued.

PRODUCT PIPELINE

The company has developed a platform technology that can support all clinical settings - see graph below. Its first pain assessment device – the PMD200TM – is intended to support pain management of patients undergoing surgery in the operating room. PMD-200 is currently in beta testing. Clinical studies, intended to validate the performance of the system and the corresponding Pain Index calculated and displayed on the monitor, are being performed in major medical centres in the U.S, Europe and Israel.

MANAGEMENT

Galit Zuckerman, CEO, Director. Medasense Founder. Management and R&D positions in Applied Materials, Siemens and Nice. Walter Tabachnik, VP BD, Director. Exec VP and CFO of Oridion Systems; Covidien’s Director of Strategy and Portfolio EMEA. Noam Racheli, VP R&D. R&D in brain technology companies (monitoring and therapy).Aviad Yeshaya, VP Operation and Engineering. Operational and engineering management, medical industry and defense R&D. Kalman Kaufman, Chairman. VP, Applied Materials; President, KLA Instruments, and General Manager, Kulicke & Soffa, Israel. Shmuel Cabilly, PhD, Director. Co-founder and a CSO of Ethrog Biotechnology, Director, Redhill Biopharma Ltd.Udi Gafni, Director. Chairman and CEO, Medoc Advanced Medical System Ltd.


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

CONTACTEduardo Margallo CEO

ADDRESS Medlumics S.L. Ronda de Poniente 16, 1E Tres Cantos 28760 SPAIN

TELEPHONE +34 91 803 39 25

FAX +34 91 804 93 21


YEAR FOUNDED2011

MedLumics S.L. www.medlumics.com

FINANCIAL SUMMARY

MedLumics is looking for 9M€ in equity funding to support the development and regulatory approval of an image guided RF ablation catheter for the management of cardiac arrhythmia. This Series B round take the company to first-in-human safety trials, CE Mark and initial sales. Based on first clinical results, an exit window in 2017 could be available for investors.

Key company financials in the period 2015-19. Amounts in k€

2015 2016 2017 2018 2019

Turnover 0 0 2.200 11.000 31.046

EBIT -3.011 -3.932 -6.579 -1.144 7.535

Share Capital 7.860 11.860 11.860 11.860 11.860

Headcount 21 23 34 36 44

COMPANY PROFILE

MedLumics is a medical imaging company developing a new generation of clinical systems that produce high resolution sectional images of human tissues. Its products are based on optical coherence tomography (OCT), an established imaging modality in ophthalmology with fast growing applications in dermatology, cardiology and other fields of medicine.

The company, a Spanish start-up established in Madrid in 2011, has completed the development of an integrated optics platform that allows it to reduce the size and complexity of final instruments while offering uncompromised image features. MedLumics has demonstrated the miniaturization of a complete OCT system into an inexpensive optical microchip with a footprint of only 2x20mm2. The company has developed a first-in-class portable skin imaging system combining OCT and video dermoscopy, which is currently in regulatory phase and will be commercialized from a separate spin-off organization.

MedLumics’ unique technology, encompassing a flexible photonics process, allows for miniaturization of final systems in the context of disposable endoscopic and catheter-based applications. Chip design is done in house and forms a strong proprietary know-how basis. Co-development of an application-specific silicon photonics process has allowed the company to establish an exclusive R&D agreement with its manufacturing laboratory. Ten patent families form the company’s IP portfolio, organized in three layers of protection (fabrication, system design and products) and built in collaboration with specialized IP lawyers in US. Seven additional concepts are currently in the disclosure phase. FTO studies for the platform and its catheter-based application are available.

The company has created a quality culture focused on compliance with ISO 13485; ISO 9001 certification was obtained in 2014.

To date, Medlumics has raised 3.5M€ in private equity from Ysios Capital Partners and Caixa Capital Risc. Public funds in an amount of 2.5M€ have been obtained from competitive R&D programs at European and national level.

The company is now seeking a Series B round of 9M€ to fund the development and regulatory approval of an image guided RF ablation catheter for the management of cardiac arrhythmia.

TYPE OF COMPANY

Private

Continued...


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u



TELEPHONE +34 91 803 39 25

FAX +34 91 804 93 21


YEAR FOUNDED2011

...continued

DEVELOPMENT FOCUS

Miniaturized optical imaging for diagnosis and therapy guidance.


1. Series B round of 12M€ to fund the development and regulatory approval of an image guided RF ablation catheter for the management of cardiac arrhythmia.

2. Licensing-out of miniaturized imaging platform in non-competing clinical areas.

3. Licensing-out/global distribution agreement for NITID™, first-in-class portable dermoscope + OCT dermatology product.

PRODUCT PIPELINE

1st Product: NITID™

First hand-held product worldwide for the diagnosis of skin tumors using OCT-based histology information and combined video dermoscopy.

Opportunity: Worldwide dermatology diagnostic imaging market, 247M$/yr.

Product Stage: Regulatory filing

Pre-launch: October 2014

Drivers: Non-surgical treatments & false positives driving demand for imaging.

Competition: Agfa Healthcare, Michelson Diagnostics (OCT), Derma Medical Systems and FotoFinder (Dermoscopy) Caliber - Confocal Microscopy.

Product benefit: In this field, Medlumics has the unique ability to provide a high-quality OCT at a cost compatible with general adoption. The first worldwide hand-held device incorporating standard dermoscopy allows for seamless integration with current clinical workflows, which is crucial for this imaging technique to be used in daily practice.

2nd Product: RF Ablation

OCT-guided RF ablation therapy with direct evaluation of lesion formation to improve atrial fibrillation treatment.

Opportunity: >1.3B$/yr.

Product Stage: Technology Development

Exp. Launch: 2016Q4

Drivers: Lack of satisfactory pharmacological options for atrial fibrillation together with a very large and increasing disease incidence drive demand for RF ablation procedures. Still, high recurrence and long cath-lab times call for improved RF systems.

Competition: Biosense Webster, St. Jude, Boston Scientific, Biotronik, Abbott.

Product benefit: Medlumics’ unique technology is able to provide a catheter design combining tissue imaging during the ablation procedure with optical sensing of relevant procedure parameters and state-of-the-art treatment instrumentation. Pre-clinical results show that ablation can be accurately monitored on the basis of molecular tissue composition. This allows for controlled lesion formation and intraprocedural verification of continuity, reducing recurrence rates and cath-lab time.

continued...



PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u



TELEPHONE +34 91 803 39 25

FAX +34 91 804 93 21


YEAR FOUNDED2011

...continued

MANAGEMENT

Eduardo Margallo, PhD, President & CEOPioneer in the photonic integration of optical coherence tomography, with a strong background in business administration and management.

Jose Luis Rubio, PhD, VP & CTOExpert in medical imaging with a deep understanding of the challenges and potential of optical coherence tomography based on integrated optics, and an specialization in IP and innovation management.

Miguel Eslava, VP & COOEx-general manager at GE Healthcare for Spain and Portugal, with a strong international business network and a solid experience (over 30yr.) in operations, quality management and team leadership.

Advisory boardProf. Dr. Wolfgang Drexler: One of the pioneers of OCT, currently he leads the Center for Biomedical Imaging and Physics at the Medical University of Vienna.

Dr. Wolfgang Reim, Independent DirectorEx-CEO of Dräger Medical and member of the board of Drägerwerk for 7 years, he served as president of the ultrasound division of Siemens Healthcare and in other leadership positions in the medical device industry. He is currently on the boards of Carl Zeiss Meditec AG, GN Store Nord A/S, Esaote SpA and Elekta AB.



PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

CONTACTNicolas Weber Managing Director

ADDRESS Reinhardtstr. 23-27 Berlin 10117 Germany

TELEPHONE +49 (170) 962 7432


YEAR FOUNDED2011

FINANCIAL SUMMARY

2012 2013 2014 2015 2019 stable

# of modalities 1 2 4 14 106 106

revenue 0.3m 1.5m 4.0m 14.4m 71.4m 55.5m

EBITDA -0.5m 0.3m 1.5m 0.4m 11.0m 21.0m

EBIT -0.6m -0.1m 0.8m -1.0m 4.7m 14.5m

new equity 3.5m – – 15.0m

new loans 0.9m 0.9m 1.6m 3.9m 2.6m

balance sheet 3.1m 4.5m 6.2m 24.8m 37.7m

all medneo companies consolidated | all numbers in EUR | 2012 & 2013 are actual

2014 are rolling forecast figures

2015 based on actual leads with new product medneo franchise incl. infrastructure sales

2019 incl. further scaling w/ new projects | stable year equals 2019 w/o new projects

COMPANY PROFILE

medneo is a company based in Berlin specialized in “Radiology as a Service” with own highly efficient operated diagnostic centers and an international teleradiology network. medneo offers its customers (physicians, hospitals, research institutes etc.) fully-equipped imaging platforms including the entire non-medical operation of the diagnostic value chain. The final product is a “clinical image” as alternative for customers to buy “medical technical equipment” and operate the technology by themselves. medneo achieves cost leadership in the set-up and operation of high-end diagnostic centers by standardization and digitalization of the entire diagnostic value chain and by economies scale with a high utilization of cost intensive technology infrastructure. Beside the operation of own diagnostic centers in European countries, medneo offers a franchise model to ensure a rapid growth in international markets. The business model and the innovative IT developments of medneo enable a high scalability of the radiology business.

Today medneo operates two centers with four high-end imaging modalities for 30+ customers with 50+ employees. With this setup medneo made the proof of concept, proof of market and proof of profitability for this new business model. The utilization rates of the medical technology were doubled compared to market average. The cost position is up to 40% lower than in traditional radiology settings while offering the most innovative diagnostic equipment available. The first MRI was installed mid-2012, the last modality went live in July 2014. The next projects and a strong sales funnel to open up additional imaging platforms in Germany as well as international are in place. In 2014 revenues of EUR 4.0m (x2.5 vs. 2013) will be reached. The break-even (accumulated incl. depreciation) was achieved mid-2014 while developing new products and setting-up a company ready to scale.

TYPE OF COMPANY

Private

DEVELOPMENT FOCUS

Diagnostic imaging market.


medneo can grow with its existing cash flow. In order to scale faster in Germany and international markets the founders seek a series B partner to invest EUR 15m in equity.

Continued...

medneo GmbHwww.medneo.de


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

CONTACTNicolas Weber Managing Director

ADDRESS Reinhardtstr. 23-27 Berlin 10117 Germany

TELEPHONE +49 (170) 962 7432


YEAR FOUNDED2011

...continued

PRODUCT PIPELINE

Beside the operation of own diagnostic centers in European countries, medneo offers a franchise model to enable a rapid growth in international markets supported by sales co-operation with strategic and global acting partners (e.g. Siemens and Philips). The business model and the innovative IT developments and SOPs of medneo make the radiology business scalable.

medneo operations consists of operated diagnostic platforms with high-end diagnostic imaging modalities. medneo invests, builds and operates these centers with own non-medical staff with strong focus on efficiency. Countries in scope are Germany and selected developed markets. This “shareconomy” approach offers radiology services as a “pay-per-use” model to different customer groups (physicians, hospitals, research institutes etc.). The business concept is unique in the market and has been examined in detail by a renowned Berlin law company.

medneo franchise consists of imaging platforms with high-end diagnostic modalities. The franchisee invests, builds and operates these centers according to medneo specifications and SOPs in international markets. Beside infrastructure, IT and medical technical technology (turn-key) the required process know-how as well as operation support via unique medneo elements like remote control of medical equipment and teleradiology is part of medneo’s offering. medneo receives an initial fee as well as a fee per patient as business model. Target groups are investors, health insurance companies, health ministries as well as hospital chains which are able to open multiple centers within their regional markets.

MANAGEMENT

André Glardon Dr. Matthias Issing Nicolas Weber

medneo GmbHwww.medneo.de


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

CONTACTLudwig Gold CEO

ADDRESS Gumpendorferstraße 139 Vienna 1060 Austria

TELEPHONE +43 1 236 65 76 16

FAX +43 1 236 65 76 22


YEAR FOUNDED2008

FINANCIAL SUMMARY

• Commercialization starting in 2015

• Sales development based on distributor model from EUR 0,3mio in 2015 up to EUR 50 mio in 2019

• Reimbursement process to be started in several European markets (GER, UK, FRA, BEL, TUR)

• 2 financing rounds successfully closed

• C-round for commercialization and randomized, multi-center trial in Europe with EUR 10 mio to be raised

COMPANY PROFILE

Cutting-Edge Cardiac Care

Miracor Medical Systems GmbH is an Austrian medical device company dedicated to improve clinical outcome of patients with impaired cardiac function.

The company was founded in May 2008 by Professor Dr. Dr. Werner Mohl and the European venture capital firms Earlybird and Delta Partners including SHS as of 2011.

Miracor develops and commercializes the CE-marked PICSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System consisting of a driving console and associated catheters for improving outcomes for severe heart attack patients. The Miracor PICSO Impulse System seeks to increase blood flow to the affected heart tissue, thereby improving the overall heart function after a heart attack.

Recent Pre-Clinical and Clinical Studies have successfully demonstrated the positive effects of PICSO on infarct size reduction in acute heart attack patients.

The company is conducting further post-market clinical trials to document the safety and effectiveness of the PICSO Impulse System in heart attack patients undergoing coronary revascularization with percutaneous coronary intervention (PCI-stenting).

TYPE OF COMPANY

Private

DEVELOPMENT FOCUS

Heart Attack Therapy.

MANAGEMENT

Ludwig Gold, CEO Lars Schiemanck, CTO Roger Kessels, Clinical Director Cajetan von König, Director Sales & Marketing

Miracor Medical Systems GmbH www.miracormedical.com

Miracor PICSPO Impulse Catheter

Miracor PICSPO Impulse Console


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

CONTACTJørgen Thorball CEO

ADDRESS Platz 4, D4, Root [Lucerne] CH-6039 Switzerland


YEAR FOUNDED2013

FINANCIAL SUMMARY

Series A completed. Pre-IPO round expected 2015.

COMPANY PROFILE

Ophiuchus Technologies is committed to developing its proprietary regenerative cell technology, DrSC™ Neural in order to provide physicians with a new and efficient tool for the treatment and functional restoration of injured brain and spinal cord tissue.

Ophiuchus Technologies is an operational spin-out company of the NOVAGENESIS FOUNDATION, a charitable R&D organisation. Holding exclusive product and marketing rights to DrSC™ Neural for neuronal injury related indications, such as traumatic spinal cord injury and traumatic brain injury, Ophiuchus has the ambition to treat millions of patients worldwide.

TYPE OF COMPANY

Private

DEVELOPMENT FOCUS

To launch the world first commercial product for neuron replacement and repair of traumatic spinal cord and brain injuries. Other indications to follow.


Product launch 2015 to serve the private patients on the waiting list and Early Access Program.

PRODUCT PIPELINE

DrSC™ Neural – Phase I/II Traumatic Spinal Cord Injury [The world’s first directly re-programed stem cells]

MANAGEMENT

Jørgen Thorball, CEO

Ophiuchus Technologies AG www.ophiuchustechnologies.com


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

CONTACTBo Qwarnstrom CEO

ADDRESS Virdings Allé 2 Uppsala SE-75450 Sweden

TELEPHONE +46(0)185 539 93


YEAR FOUNDED2011

FINANCIAL SUMMARY

OssDsign has raised €3 million in its first two financing rounds and an additional €1 million in non-dilutive funds. In its third financing, OssDsign seeks €7 million for commercial expansion, divided in two tranches: the first €2.5 million and the second €4.5 million. The company has started commercialization with its lead product OssDsign® Craniomosaic.

COMPANY PROFILE

OssDsign´s vision is to become the cutting edge worldwide leader of solutions for better bone repair. The first step in the strategy is to establish OssDsign® Craniomosaic – the first implant allowing functional healing in cranioplasty – among neurological and craniofacial surgeons. Functional healing means integration between the synthetic implant material and surrounding tissues leading to better healing, less complication rates, higher quality of life for patients and reduced hospital costs. OssDsign has developed unique proof of bone remodelling in large cranial defect treatment. Second step: Launch follow-up bone repair products, based on the company´s proprietary technology platform, to the same target groups. Third step: with strategic partners, introduce the clinically and commercially established product concepts on larger market segments, such as oral surgery, spine and trauma. OssDsign has started sales of OssDsign® Craniomosaic in selected EU countries. Follow-up products are under CE marking. Moreover, OssDsign´s product for cranial fixation: Cranioplug, received in Oct 2015 FDA 510(k) clearance. By 2017, the target of OssDsign is to be a leader in the market for patient specific implants for cranial repair. The company is now raising capital in a third financing round to fund the next phase of the company´s expansion.

TYPE OF COMPANY

Private

DEVELOPMENT FOCUS

Implants and bone replacement products for bone repair with cranial repair as lead indication.


OssDsign is seeking investors for the current financing round.

PRODUCT PIPELINE

OssDsign® Craniomosaic for cranioplasty. EU – Commercial

OssDsign® Cranioplug for cranial fixation. EU – Under CE marking US – 510(k) clearance

Other products under development based on technology platform.

MANAGEMENT

Bo Qwarnstrom, CEO, founder with 30 years + from executive positions in medtech industry. Dr Thomas Engstrand, parttime CMO, founder and part-time senior craniofacial surgeon at the Karolinska University Hospital.Dr Håkan Engqvist, parttime CSO, founder and professor in biomaterials at the Uppsala University. Dr Jonas Åberg, founder and development manager.Eva Nicklasson, operations manager

OssDsign AB www.ossdsign.com


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

CONTACTDr. Marie-Christine Fluet CEO and founder

ADDRESS Leonhardstrasse 27, LEO B9.2 Zurich 8092 Switzerland

TELEPHONE +41 44 632 9188


YEAR FOUNDED2013

FINANCIAL SUMMARY

Based on preliminary sales predictions and cost estimation of our diagnostic test, the company will reach break-even in 2018. A turnover of 9.4 MCHF in 2019 is estimated. An initial funding of 2.8 MCHF will be needed. These funds will serve in the development of the product, development of the company and acceleration of market entry.

COMPANY PROFILE

At ReHaptix, we shape the future of neurorehabilitation, we disrupt the way patient are assessed by providing in depth objective diagnostic with no human bias and empower patients about their health and recovery. We design and develop automated and computer-based methods for patients and healthcare professionals in neurorehabilitation filling an unmet medical need by providing objective, sensitive and repeatable measures of impairments in a highly flexible setup at the clinic or at home where patients can perform the tests autonomously for continuous monitoring. We believe that a precise assessment is the basis for an effective and personalized patient’s rehabilitation program. Our product tracks the patient’s progress in few minutes and allows adapting the therapy to accelerate patient’s recovery towards its independence. We believe that each patient needs to be treated equally independently of his age, gender and social class.

TYPE OF COMPANY

GmbH

DEVELOPMENT FOCUS

Diagnostic of arm and hand sensorimotor impairments of patients suffering from a neurological disorder.


We are looking for a total of 2.8 MCHF. 1 MCHF will be needed in 2015 to develop the prototype, 1.2 MCHF will be needed in 2016 to develop the final product and 0.6 MCHF will be needed in 2017 to market the product.

PRODUCT PIPELINE

ReHaptix has developed a first generation prototype that has been tested by clinical partners in Switzerland, Belgium and Canada. Based on the feedback collected from the use of the device, ReHaptix is reshaping its product and is developing the second generation prototype. A patent application is in progress and no details about the product can currently be provided. The new solution comprises software and hardware. A first working prototype of the software has been developed comprising one diagnostic test. We plan on developing two additional tests by Q2 2015. The development of the first prototype of the hardware is planned for end of 2015 while the final product should be ready end of 2016. The final product will be launched in 2017.

MANAGEMENT

The team is composed of the two founders who bring complementary skills and both have a strong interest for medicine. Dr. Marie-Christine Fluet has a background in electrical engineering and a PhD in neurosciences. Dr. Fluet was postdoctoral researcher at the Rehabilitation Engineering Lab (RELab) of the Swiss Federal Institute of Technology Zurich during which she worked on the development of robotic devices for diagnostic. She now holds the CEO position at ReHaptix. Sophie Winkler-Payot has a M.A. in Finance and Economics from University of St. Gallen (HSG), and has 9 years of experience in investment banking and private equity. At ReHaptix, she holds the COO position.

ReHaptix rehaptix.com


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Spectromics www.spectromics.com

CONTACTNeil Butler CEO

ADDRESS Core Technology Facility, 46 Grafton St. Manchester M13 9NT UK

TELEPHONE +44 (0)1580 891106


YEAR FOUNDED2014

FINANCIAL SUMMARY

First year of operation, pre-revenue.

COMPANY PROFILE

Spectromics is an in vitro diagnostics company formed in 2014 with proprietary and game-changing technology developed at Manchester University. For the first time healthcare workers will be able to use a rapid, point-of-prescription, diagnostic to guide the effective use of antibiotics.

A major cause of growing antibiotic resistance is that patients are mistreated with anti-infectives and the issue is greatest in primary care settings where diagnostics are not used to guide antibiotic treatment because microbiology tests take days. The Spectromics solution is a 10 minute test that fits within a doctor / patient appointment. The test determines whether a bacterial infection is present, and if so which antibiotic most effectively treats the infection. The test is “phenotypic” so it will adapt and keep pace with new resistance mechanisms as they occur.

This novel and proprietary technology was developed at the Manchester Institute of Biotechnology. A large number of studies have tested hundreds of strains of pathogen, together with antibiotics with differing modes of resistance, and with different sample types.

The low cost disposable cartridge comprises a “closed tube” design, so the potentially infectious sample is contained. Excellent product stability should allow the products to be used across broad geographical markets. The instrument will be battery operated, ideal for Global Health markets.

Despite the rising incidence of antibiotic resistance, we still have a large number of antibiotics to use against infections, using them effectively will reduce the escalation in resistance, and allow conservation of last-line antibiotics. The test will advise healthcare users which antibiotics, out of a panel of 8, which will be effective for each patients infection and provide a “traffic light” antibiotic stewardship recommendation:

– Green: Old drugs with an excellent cost and safety profile. Currently shelved due to having a resistance of circa 50%, for the right patient these are ideal and each could treat half the patients.

– Orange: Front-line drugs used empirically today, we should be conserving these to prevent undue increase in their resistance.

– Red: Last-line drugs, should be conserved at all costs for future battles against serious infections.

The business will stay focussed on the science, working with subcontractors to develop and manufacture both the instrument and disposable cartridge. Following the development of the Point-of-Prescription system, the company will then apply the technology for high throughput rapid lab susceptibility testing such as positive blood cultures for sepsis.

The company will seek early trade sale opportunities to realise investor return.

TYPE OF COMPANY

Private

DEVELOPMENT FOCUS

Infectious disease.


• Currently raising a Euro 1.25m seed investment round, which is anticipated to lead to a Euro 3.75m Series A in year 2 and Euro 5m Series B in year 3.

• Interest in discussions with branded generic companies regarding companion dx relationship.

• Interest in discussions with diagnostic / medtech companies regarding distribution relationship.

Continued...


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Spectromics www.spectromics.com

CONTACTNeil Butler CEO

ADDRESS Core Technology Facility, 46 Grafton St. Manchester M13 9NT UK

TELEPHONE +44 (0)1580 891106


YEAR FOUNDED2014

...continued

PRODUCT PIPELINE

The first test is for urinary tract infection, the largest bacterial infection in man, accounting for 15% of all community prescribed antibiotics. Initial targeted settings are GP surgeries and pre-natal clinics where a majority of UTI infections are treated today. Fast effective treatment during pregnancy is especially important to ensure that infections are not undertreated, when they can lead to kidney infections and pre-term births, or over-treated where a bacterial infection is not present and the child is born with an unnecessary, increased antibiotic status. The test will also have utility in ER settings where 30% of UTI cases present due to patients feeling unwell and with a fever. By early triaging of such patients in ER settings treatment costs can be largely avoided (ER costs are10x higher at $2,000/ patient than in primary care according to the study carried out by the Henry Ford Hospital). 25% of all sepsis cases originate from a UTI. Additional tests will later be developed for tonsillitis and strep throat for use in primary care. Later applications will focus on acute care life-threatening infections in ER settings.

MANAGEMENT

Neil Butler, CEORoy Goodacre, DirectorMathew Upton, Director


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

CONTACTMatthew H.J. Kim Chairman & CEO

ADDRESS 701 Brickell Avenue, Suite 1550 Miami 33131 U.S.A.

TELEPHONE +1-305-728-5382

EMAIL Matthew.Kim @vigilantbiosciences.com

YEAR FOUNDED2011

FINANCIAL SUMMARY

Pre-revenue.

COMPANY PROFILE

Vigilant Biosciences, Inc. (“Vigilant”) is a oncology-focused company providing early intervention for better outcomes. Our initial products include a quantitative lab assay as well as an oral rinse and test strip kit for head and neck squamous cell carcinoma (HNSCC). The products are scheduled for product launch in 2015 to compete in the $3.9B US and $10.2B global HNSCC markets..

TYPE OF COMPANY

Private

DEVELOPMENT FOCUS

Oncology • Diagnostic • Medical Device


Investment | Series C: $15MM - $20MM

Licensing Out | Reference Lab Kit & Point-of-Care Test Strip for Oral Cancer

Licensing In | Cancer biomarker and imaging technologies.

PRODUCT PIPELINE

Oral Cancer Reference Lab Kit (CE anticipated Q1 2015)

Oral Cancer Point-of-Care Test Strip (CE anticipated Q2 2015)

Development: Esophageal • Lung • Bladder • Cervical

MANAGEMENT

Matthew H.J. Kim, J.D., Chief Executive OfficerElizabeth Franzmann, M.D., Chief Scientific OfficerRobert Bohannon, Ph.D., Technology & Product DevelopmentJoe Zack, Marketing & SalesDavid Warar, Business DevelopmentJohn Comisi, D.D.S., Chief Dental OfficerRobert Hamilton, CPA, Chief Financial Officer

Vigilant Biosciences, Inc. www.vigilantbiosciences.com


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

CONTACTEdvardas Satkauskas Managing Director ADDRESS Saul€s g. 39-10 Kaunas LT-51362 Lithuania

TELEPHONE +37 061 462 045


YEAR FOUNDED1993

COMPANY PROFILE

Vittamed is a neurodiagnostics medical device company with offices in Kaunas, Lithuania and Boston, USA. The company has developed a suite of ultrasound-based devices to non-invasively measure the absolute value of intracranial pressure (ICP), real-time cerebral blood flow autoregulation (CA), and intracranial volumetric wave monitoring. The non-invasive diagnostic methods have been clinically tested and proven in leading neuro centers in Europe and the United States.

TYPE OF COMPANY

Private

DEVELOPMENT FOCUS

Non-invasive Ultrasound based Neuromonitoring & Diagnostics.


Vittamed is seeking for distribution and strategic partnership to introduce Vittamed products in global markets. Vittamed is open for strategic partnership with leading industry’s companies.

Vittamed is raising 7-10M Series USD B investment for commercialization in Europe, Australia, and other countries; and achieve FDA approval and start US commercialization.

PRODUCT PIPELINE

Non-invasive neuromonitoring and diagnostic technologies:

Non-invasive ICP meter Vittamed 205 offers a fast, safe, and easy to use method of accurately, precisely and reliably measuring ICP. Vittamed 205 applies controlled external pressure (Pe) to the tissues surrounding the eye ball and uses two-depth Doppler ultrasound to compare simultaneous blood flow parameters in two contiguous segments of the ophthalmic artery (OA) – the intracranial and extracranial segments. The device directly compares ICP and Pe values and can identify the balance ICP=Pe when blood flow pulsatilities in both OA segments are similar.

Continued...

VITTAMED www.vittamed.com


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

CONTACTEdvardas Satkauskas Managing Director ADDRESS Saul€s g. 39-10 Kaunas LT-51362 Lithuania

TELEPHONE +37 061 462 045


YEAR FOUNDED1993

...continued

Non-invasive Cerebrovascular Autoregulation monitor Vittamed 505 is based on ultrasound time-of-flight technology. A head frame with ultrasonic transducers is used to generate short ultrasonic pulses through the skull. The device measures the acoustic path through the brain (“time-of-flight”) and monitors real time cerebrovascular perfusion using Pressure Reactivity (PRx) index.

MANAGEMENT

Lithuania:Edvardas Satkauskas, Managing Director VP of Operations, 10 years experience; Medical device development, manufacturing, marketing and sales.Arminas Ragauskas, PhD, CTO, Cofounder and technology inventor; 150 patents; Professor & Head of Telematics Lab, Kaunas University of Technology.

USA:Remis Bistras, PhD, MBA, CEO, 20 years experience; commercialized and licensed more than $100 mil of assets in medtech; ex-Ciba Vision/Novartis & EyeGate Pharma; BostonT. Forcht Dagi (MD, MBA) Board member, neurosurgeon; >20 Yr. experience investing as VC in medtech; Harvard and MIT faculty appointments; Boston

VITTAMED www.vittamed.com

Supporting Organisations


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

www.biopharminsight.com

BioPharm Insight is your definitive guide to the global life sciences community. Subscribers take action on forward-looking intelligence uncovered by an independent team of investigative journalists, and make strategic business decisions using the most comprehensive and powerful real-time database of market analytics and key contacts. Featuring an intuitive online interface and exclusive Active Intel™ relational content technology, BioPharm Insight provides an unrivaled capability to segment and analyze the industry with detailed and searchable profiles.

Global Headquarters100 River Ridge Drive, Suite 204Norwood, MA 02062Tel: +1 781 762 9450Fax: +1 781 762 9400

New York330 Hudson Street, 4th FloorNew York, NY 10013Tel: +1 212 686 5606

London80 StrandLondon WC2R 0RL UKTel: +44 (0) 207 059 6307

BioPharm Insight



PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

www.biotechgate.com

Your source for life science companies and licensing information.

If you are about to negotiate a licensing deal between a Biotech and a Pharma company. Or you are looking for a big Pharma company to out-license your Biotech product. Or you are active in the medical technology (Medtech) sector and just want to identify potential cooperation partners or customers. Or you are an investor looking for investment opportunities - or you just want to know about historical financing rounds and valuations in the life sciences, Biotech, Pharam and medical device field. This portal can solve all of these problems - and even more.

Biotechgate



PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

www.citigatedr.co.uk

Citigate Dewe Rogerson is the leading international consultancy specialising exclusively in financial and corporate communications across the UK, Europe, North America and Asia.

Citigate has a dedicated Pharma & Biotech team with more than 60 years combined experience in the sector and a unique mix of skills: corporate and financial PR and investor relations, finance, journalism and academic science. The team provides sector expertise and forms an integrated part of Citigate Dewe Rogerson, benefiting from the company’s overall strength and from the cross-fertilisation of ideas across sectors.

The Citigate Pharma & Biotech team has an established track record in working with biotechnology companies at all stages in development. As well as core skills in financial calendar work, transactions support, financial PR and media relations, the team has extensive experience in branding, design and new media consultancy. Recent clients include global top-five biotechs, listed companies in the UK and Europe, and numerous emerging businesses in the UK, France, Germany, the Netherlands, and Scandinavia.

Citigate’s Pharma & Biotech team has been involved in major corporate transactions such as IPOs, other public and private fundraisings, and M&As. We have advised on a number of IPO transactions across Europe including; METabolic EXplorer (Euronext Paris - €52 million), Algeta (Oslo Stock Exchange - €30 million), Santhera Pharmaceuticals (SWX – CH88.5 million), ThromboGenics (Euronext Brussels - €35 million), Hutchison China MediTech (AIM - £40 million), Zentiva (LSE and PSE – US $211 million), Arpida (SWX - €63 million), Inion (LSE - £35 million), TopoTarget (CSE - €30 million), BioFusion (AIM - £8.2 million) and ExonHit (Alternext - 7.3 million).

Citigate Dewe Rogerson3 London Wall BuildingsLondon WallLondon EC2M 5SY

Tel: +44 (0)-207-638-9571

Citigate Dewe Rogerson



PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

www.edisongroup.com

Edison is a UK-based investment intelligence firm. It employs more than 70 equity analysts operating from offices in London, New York, Sydney, Wellington and Frankfurt that provides research coverage on more than 700 publicly traded companies, making it one of the largest dedicated small and mid-cap research providers worldwide. Healthcare is the largest industry group within Edison with 12 analysts covering some 150 biotech/medical device companies located in UK, Continental Europe, North America and Australia.

Edison



PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

FreeMind www.freemindconsultants.com

FreeMind is a consulting group whose goal is to assist its clients in maximizing their potential to receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting group of its kind with over 400 active clients, academics and Industry alike. FreeMind’s proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date.

Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations such as Michael J Fox, Bill and Melinda Gates and Susan G Komen.

FreeMind’s knowledgeable and experienced team of Analysts and Project Managers are dedicated to guiding its clients non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of experts will assist our clients in making non-dilutive funding a key tool in their long-term financial strategy.

Tel: (617) 648-0340 Fax: (617) 904-1767 Email: [email protected]

BostonFreeMind Group423 Brookline Ave. #124Boston, MA 02215

Washington DCFreeMind Consultants4094 Majestic lane # 269Fairfax, VA 22033

JerusalemFreeMind GroupHi - Tech CenterHebrew UniversityJerusalem 95702Israel



PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

GoingPublic Magazin www.goingpublic.de/lifesciences

GoingPublic Magazin is a modern capital markets publication for securities issuers and investment professionals. The monthly magazine (together with 4 special issues and 6-10 special supplements every year) gives issuers an insight into being public trends and investor relations issues, as well as covering any relevant capital market innovations. Leading law firms contribute their expertise in the form of specialist articles on tax and legal issues, whilst the M&A section charts developments from the spectrum of public takeovers to companies going private. GoingPublic represents the top tier of corporate finance business and is the leading IPO publication in the German-speaking regions of Europe. In addition, the magazine sees itself as being the leading public platform and as a channel for communications between issuers, institutional investors, service providers and the financial community.

For more than 15 years life sciences have been one of the key topics of GoingPublic Magazin and VentureCapital Magazin. Beside cover stories, specials and articles on transactions (deals, funding, IPOs, M&A etc.) five special issues are published per year: Flagship publication is “Biotechnology“ surrounded by specials on „Industrial Biotechnology“, „Healthcare“ „Personalized Medicine“ and „Medtech“.

The newsletter LifeSciencesUpdate offers a monthly complementary tool by reporting on latest news, highlights, events, giving cross-links and much more. Its mission is: cross-medial content (magazine – web – event) of the life sciences industry combined with knowledge from corporate finance and capital markets.

GoingPublic Media AGHofmannstr. 7a81379 MünchenTel.: 089 – 20 00 339 – 0Fax: 089 – 20 00 339 – 39



PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

HealthCapital

The Healthcare Industries Cluster Berlin-Brandenburg – HealthCapital – is one of the leading life sciences and healthcare centers in the world. The unique research and clinic landscape, which is the region’s major strength, is supported by a close network of key players from industry, start-ups, finance, clinics and politics. Here, numerous technology parks and networks in different fields, above all biotechnology and medical technology, create an excellent infrastructure for transforming the latest scientific findings into innovative products and services for the healthcare sector. Berlin Partner for Business and Technology is responsible for managing the cluster in cooperation with ZAB Brandenburg Economic Development Board.

www.healthcaptial.de



PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Instinctif Partners

Instinctif Partners is an international business communications consultancy. With a track record of delivering truly creative programmes, the Life Sciences practice focuses on enhancing the value proposition for companies seeking investment, partnerships or customers. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting communications solutions that showcase each company, product or technology. Specifically, we are unique in offering specialist expertise seamlessly across corporate, financial, healthcare and marketing communications with outreach programmes to media, industry, professional, public, financial and investment communities. Our service offering covers all communications disciplines including strategic counsel, PR, IR, media relations, public affairs, crisis communications, internal communications, marketing, advertising, copywriting, design, research and event management. Our globally integrated and dedicated life sciences team serves clients around the world from our bases in London, Manchester, Munich, Boston, Melbourne and Sydney.

For more information please visit www.lifesciences.instinctif.com

www.lifesciences.instinctif.com



PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Labiotech.eu

LaBiotech.eu is the free and extensive European biotechnology news website. Launched in September 2014, this young and dynamic media is the best way for you to keep a watch on the business and innovations of biotechnologies. Thanks to our partnerships with major european biotech events we are also your dedicated website for event summaries and agenda. You can also subscribe to our weekly newsletter to receive the latest news.

http://labiotech.eu



PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Life Science Austria

Life Science Austria – LISA – is a program acting as a hub for people from all over the world who are interested in the life science sector in Austria. Together with its associates in the Austrian regions, LISA is the first point of contact for anyone with questions about scientific collaboration, setting up an operation, or funding and sponsoring projects and businesses in Austria.

Working with all existing life science clusters in the Austrian regions – ecoplus, human.technology.styria, Life Science Austria Vienna Region, Health Technology Cluster, and Life Science Cluster Tirol - LISA is able to build on their expertise and services. The aims of LISA and its partners are: contribute to the success of life science enterprises in Austria by helping to introduce scientific discoveries to the market, assist in the search for funding, and provide general business consultancy and support to ensure healthy commercial development.

Austria Wirtschaftsservice GesmbH (aws), is responsible for running this program on behalf of the Austrian Federal Ministry of Economics, Family and Youth (BMWFJ).

Austria Wirtschaftsservice Gesellschaft mbH, Ungargasse 37, 1030 Wien, Austria

Tel.: +43 (1) 501 75 - 0 • Fax: +43 (1) 501 75 - 900 • Email: [email protected]

www.lifescienceaustria.at



PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

MedTech Europe

MedTech Europe is an alliance of European Medical Technology Industry Associations. The alliance was founded by EDMA, representing the European In Vitro Diagnostic Industry, and Eucomed, representing the European Medical Devices Industry.

Medical technology brings many benefits. First and foremost, it makes a positive difference to the lives of people all over the world. Many people now live healthier, more productive and independent lives as a result of the innovations the medical technology industry has delivered. Furthermore, medical technology is also improving the productivity and efficiency of healthcare systems, as well as driving economic growth.

The medical technology sector does not only consist of medical device and in-vitro diagnostics manufacturers, but also includes medical service providers, manufacturers of radiological equipment and medical accessory manufacturers.

MEDTECH EUROPERue Joseph II, 40B - 1000 BrusselsBELGIUM

Tel: +32 (0)2 300 96 43 Fax: +32 (0)2 300 96 44 Email: [email protected]

www.medtecheurope.org



PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Swiss Biotech Association www.swissbiotech.org

Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services.

The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland’s profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies.

Swiss Biotechs’ mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry. The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process.

Further inquiries:SwissBiotech, Executive OfficeTel. +41 (0)44 455 56 78 [email protected]



PANIESORGANISERS

WELCOM

ESPEAKERS

t back

www.tiberendstrategicadvisors.com

Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics. We work with both public and private emerging growth companies.

1. To enhance valuation

2. To build visibility for partnerships and strategic alliances

Tiberend Strategic Advisors, Inc.35 W. 35th Street, 5th Floor, New York, NY 10001-2205

Tel: 212.827.0020Fax: 212.827.0028 Fax

Tiberend Strategic Advisors, Inc.

Organisers


PANIESORGANISERS

WELCOM

ESPEAKERS

www.sachsforum.com

Sachs Associates Ltd is a London-based company, which organises and produces securities and emerging markets conferences in association with major exchanges and news agencies. Sachs Associates is dedicated to the highest quality standards in conferencing and, as a result, produces only a limited number of events each year. Sachs Associates investment conferences focus on Emerging Markets, European Equities and Technology, and are held in major financial centres such as London, New York and Zurich. Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.

The benefits of conference participation with Sachs Associates may be summarised as follows:

Multimedia ExposureSachs Associates is uniquely able to provide its conference sponsors maximum exposure across extremely well focused electronic and print media. Regular extensive coverage of all the Company’s conferences is carried out through video streaming and extensive events coverage through major international financial news agencies,including Bloomberg, Dow Jones and Reuters. In addition, Sachs Associates has a number of long establishedrelationships with other financial press organisations globally, which allow further effective distribution onbehalf of its clients.

Eminent SpeakersSachs Associates is committed to ensuring that its events continue to provide forums with the participation ofthe most eminent speakers from the public and private sectors. Through its reputation and its long-establishedlocal relationships, the Company has attracted very senior political and economic personalities as speakersat its events.

Sponsorship and Marketing Opportunities for forthcoming eventsSachs Associates has developed an extensive knowledge of the key individuals operating within the Europeanand global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at theforefront of the industry and provides a powerful tool by which to increase the position of your company in thismarket.

Sponsorship of any of our events allows you to raise your company’s profile directly with your potential clients.All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most outof attending our industry driven events.

The following sponsorship and marketing opportunities are available at future conferences:• Conference Sponsor – including workshops and social events• Exhibition stands• Distribution of Promotional Material

If your company is interested in exhibiting or sponsorship opportunities please callMina Orda on +44 203 463 4890.

Sachs Associates


PANIESORGANISERS

WELCOM

ESPEAKERSWe look forward to seeing you at:

3rd Annual CANCER BIO PARTNERING and INVESTMENT FORUM

Promoting Public & Private Sector, Collaboration & Investment in Drug Development

23rd February 2015 • New York Academy of Sciences

8th Annual EUROPEAN LIFE SCIENCE

CEO FORUM & EXHIBITIONPartnering & Investing in Biotech & Pharma Industry

3rd – 4th March 2015 • Hilton ZurichA irport Hotel

www.sachsforum.com

ME

DT

EC

H &

DIA

GN

OS

TIC

S I

NN

OV

AT

ION

S S

UM

MIT

27 Belsize LaneLondon

NW3 5QS

Tel: +44 203 463 4890Fax: +44 (0) 207 691 7919

Documents

SPEAKERS 2nd ANNUAL MedTech & Diagnostics Innovations … · SUPPORTING ORGANISATIONS PRESENTING COMPANIES ORGANISERS WELCOME SPEAKERS 2nd ANNUAL MedTech & Diagnostics Innovations